


SPHHP Research Activities Newsletter

University at Buffalo

June/July 2020

IN THE NEWS


Congratulations to the Following Awardees!



Jacob Bleasdale, PhD student in Community Health and Health Behavior received a new fellowship award from embrace Western New York for the project entitled, *Understanding Factors Influencing Treatment Outcomes among People Living with HIV*. The study will explore various social factors that influence treatment outcomes among people living with HIV in WNY. **Sarahmona Przybyla**, Assistant Professor of Community Health and Health Behavior, serves as Mr. Bleasdale's mentor.



Amanda Crandall, PhD student in Community Health and Health Behavior received a continuation fellowship award from the National Institute of Diabetes and Digestive and Kidney Diseases/NIH for the project entitled, *An Investigation of the Effects of Food Scarcity on Reinforcement Policy among Parents and Offspring*. The study will continue to examine the effects of financial food scarcity on food reinforcement and delay discounting among children and adolescents to improve our understanding of the risk factors for obesity. **Jennifer Temple**, Associate Professor of Exercise and Nutrition Sciences, serves as Ms. Crandall's mentor.



Rachael Hageman Blair, Associate Professor of Biostatistics, is Co-I on two new awards. The first is from the National Institute of Allergy and Infectious Diseases/NIH (Contact PI: Elsa Bou Ghanem, Microbiology & Immunology) for the research project entitled, *Genetic susceptibility to mucosal infections with aging*. The award will study two common infections in older adults, pneumonia and urinary tract infection. Using mouse models, the project seeks to determine whether host genetics can alleviate age-driven susceptibility to mucosal infections.

The second new award is from the US Army Medical Research Acquisition Activity (PI: Murali Ramanathan, Pharmaceutical Sciences) for the project entitled, *The Metabolomics-Neurofilaments-Neurodegeneration Nexus in Multiple Sclerosis Progression*. The project's goal is to characterize the role of metabolites and metabolic pathways on the progression of neurodegeneration in MS patients over 5 years old. The findings may eventually be leveraged for developing diet, lifestyle and pharmaceutical interventional strategies for preventing progression and improving outcomes for MS patients.



Gregory Homish, Professor and Chair of Community Health and Health Behavior, is PI on a continuation award from National Institute on Drug Abuse/NIH, for the project entitled, *Substance Use in Reservists: Social and Environmental Influences*. The longitudinal study is in its 8th year and continues to examine the impact of two military experiences - never being deployed and separation from military - on substance use outcomes for both soldiers and their spouses.



Kimberly Naus, Director of CAT Clients Services, is PI on a renewal award from the NYS Office of Children and Family Services for the project entitled, *Equipment Loan Closet – Renewal – 1*. The program loans adaptive equipment to legally blind persons for educational and work purposes.

Inside this issue:

In the News	1-2
Grant Clinic	2-3
NIH Funding	
Limited	4-6
RFA	6-9
PAR	9
PA	9
Fellowships	10
Individual Actions of Sustainability	10



Laura Smith, Assistant Professor of Epidemiology & Environmental Health, is PI on a new award from the Bill & Melinda Gates Foundation for the project entitled, *Participatory Systems Dynamics Modeling to Improve the Impact of Health Campaigns in Zimbabwe*. The project will use a participatory Systems Dynamics Modeling approach with government stakeholders in Zimbabwe to develop a quantitative decision-making tool to test, identify and recommend more effecting implementation approaches for health campaigns.



Gregory Wilding, Professor and Chair of Biostatistics, is Co-I on a new award from the National Institute of Alcohol Abuse and Alcoholism/NIH (PI: Elizabeth Bowen, Social Work) for the research project entitled, *Developing and Testing a Multidimensional Measure of Recovery Capital: Toward Standardized Measurement to Understand and Reduce Socioeconomic Disparities in Alcohol Recovery Outcomes*. The study seeks to advance the science of recovery from alcohol problems through development of a standardized measure of recovery capital, a theoretical construct that encompasses the ways in which physical, social, human, and cultural resources shape a person's likelihood of sustaining recovery from alcohol and other drug problems.

Dr. Wilding also is Co-I on two continuation awards. The first, from the National Institute of Nursing Research/NIH (PI: Grace Dean, Nursing), is entitled, *Efficacy of Nurse-Delivered Brief Behavioral Treatment to Self-Manage Insomnia in Cancer Survivors*. The study will continue to test a self-management behavioral intervention for cancer survivors with insomnia in order to reduce disease burden, improve well-being, strengthen self-determination and participation in health care, and prevent illness and complications.

The second is from the National Institute on Aging/NIH (PI: Kathleen Tornatore, Pharmacy) for the project entitled, *Age and Race Influences on Immunosuppression after Renal Transplant*. The study continues to seek to improve immunosuppression by creating novel dosing that integrates age, race and sex with cellular and clinical endpoints, pharmacokinetics and pharmacogenomics to attain personalized medicine.



Jihnhhee Yu, Associate Professor of Biostatistics, and **Gregory Wilding**, Professor and Chair of Biostatistics, are Co-Is on a new award from Integrity Partners for Behavioral Health (IPBH) IPA Incorporated (PI: Catherine Dulmus, Social Work) for the project entitled, *A Strategic University Collaboration to Assess the Long-Term Impact of Integrity Partners*. The project will construct and manage a data warehouse based on data obtained from the individual IPBH partner sites and other related available data sources to determine impact of IPBH on improving client outcomes to support value-based payment models.

GRANT CLINIC

General Notices

[NOT-MH-20-067](#)

Notice Announcing the National Institute of Mental Health (NIMH) Expectations for Collection of Common Data Elements

The purpose of this Notice is to announce NIMH expectations for collection of Common Data Elements (CDEs) for mental health human subjects research supported by the NIMH. Unless NIMH stipulates otherwise during the negotiation of the terms and conditions of a grant award, this Notice applies to all grant applications involving human research participants submitted after October 1, 2020. Applicants who do not plan to collect the expected CDEs should explain the rationale in the Resource Sharing Plan section of the application or potentially when Just in Time information is submitted. NIMH may seek further information regarding CDEs prior to award. The necessary funds for collecting and submitting these CDE data from all research participants to the [NIMH Data Archive \(NDA\)](#) should be included in the requested budget. A cost estimator (https://nda.nih.gov/ndarpublicweb/Documents/NDA_Data_Submission_Costs.xlsx) is available to facilitate the calculation of these costs.

[NOT-OD-20-122](#)

Guidance for Applicants Preparing Applications for the Fall 2020 Due Dates During the COVID-19 Pandemic

This Notice provides guidance for investigators and institutions preparing NIH grant applications for the May 2021 Council round, beginning with applications submitted for the September 25, 2020 due date. NIH grant applications should NOT include contingency plans that would outline steps needed to recover from temporary, emergency situations, or institutional return-to-the-workplace plans, resulting from the COVID-19 pandemic. Contingency plans will not be considered in peer review but, if needed, COVID-19 contingency plans will be requested and carefully considered by NIH staff before funding. Reviewers will continue to receive instruction to assume that temporary, emergency problems arising from the COVID-19 pandemic will be resolved and complications related to COVID-19 should not affect their scores. Reviewers will be instructed to disregard situations due to the COVID-19 pandemic, e.g., temporary declines in productivity, availability of key personnel, proposed patient populations, animal facility shutdowns, etc.

Request for Information

[NOT-CA-20-080](#)

Request for Information (RFI): Seeking Stakeholder Input on Scientific Gaps and Research Needs Related to Delivery of Cancer-related Care via Telehealth

The National Cancer Institute (NCI) is seeking information on scientific gaps and research needs related to the delivery of cancer-related care via telehealth. This request for information (RFI) is part of a planning effort designed to identify promising opportunities and set priorities for research in this area. Responses will be accepted through **July 30, 2020**. Please limit your response to two pages or less. Responses in electronic format are preferred and can be e-mailed to NCITelehealth_RFI@nih.gov. Please include the Notice number (NOT-CA-20-080) in the subject line.

Notice of Special Interests

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

[NOT-DA-20-004](#)

Research on Co-morbid Substance Use, Substance Use Disorders, and Other Psychiatric Disorders

NIDA is interested in research project grant applications that would further our understanding of co-morbidity through studies that test etiological theories and interventions (treatment and prevention), across the lifespan. The intent is to encourage a broad portfolio of research, that enhances understanding of risk, etiology, prevention, treatment and service delivery related to co-occurring conditions. Applicants should submit using the appropriate parent FOAs. **Applicants must include "NOT-DA-20-004" in box 4B of the SF424 R&R form. First Available Due Date:** October 05, 2020

[NOT-MD-20-022](#)

Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations

Projects must include a focus on one or more NIH-designated populations that experience health disparities in the United States, or a population identified as vulnerable to COVID-19 infection, hospitalization, or mortality. A list of the research topics of interest can be checked through the NOSI. **Applicants must include "NOT-MD-20-022" in box 4B of the SF424 R&R form. Expiration Date:** December 30, 2020

[NOT-MH-20-053](#)

Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19

This Notice of Special Interest (NOSI) highlights interest in research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and to future public health emergencies, including pandemics. The purpose of this NOSI is to support research to address secondary health effects of the social, behavioral, and economic changes, particularly among populations who experience health disparities and vulnerable populations through the use of digital health assessments and interventions to yield measurable near-term impact. Applicants must designate "NOT-MH-20-053" in Box 4b of the SF424 (R&R) Form. **Expiration Date:** December 30, 2020

[NOT-MH-20-055](#)

Notice of Special Interest (NOSI) in Research on Risk and Prevention of Black Youth Suicide

The purpose of this Notice of Special Interest (NOSI) is to encourage research focused on Black child and adolescent suicide. Recent data suggest that Black youth, especially those under age 13, appear to be at higher than average risk for suicide and suicide-related behaviors. **NIMH** will accept applications submitted under [RFA-MH-18-707](#), [RFA-MH-18-706](#), [RFA-MH-18-700](#), [RFA-MH-18-701](#), [RFA-MH-20-506](#), [RFA-MH-20-505](#), [PAR-19-189](#), [PA-20-185](#), [PAR-18-929](#), [PAR-18-479](#), [PA-19-091](#), [PA-18-350](#), [PAR-18-228](#), [PA-17-264](#), [PAR-19-384](#), [PAR-19-373](#), [RFA-MH-20-400](#), [RFA-MH-20-401](#). **NIMHD** will accept applications submitted under [PA-20-185](#), [PA-20-183](#), [PA-19-091](#), [PAR-19-384](#), [PAR-19-373](#). Check the website for a list of FOAs.

NIH FUNDING OPPORTUNITIES

LIMITED SUBMISSIONS

Prior approval from UB is required for the following funding opportunities. If you are interested in applying to any of the **limited submissions** listed below, please provide the OVPRED with notification through the [Limited Submissions Mailbox](#) at least 60 days prior to the sponsor's submission deadline before proceeding with an application. As of August 8, 2019, the Limited Submission Program is being managed by Dr. Joseph Balthasar, Executive Director of Research Initiatives, on behalf of the OVPRED. He may be contacted at jb@buffalo.edu or by phone at 645-3321 for any questions or advice about the limited submission process.

PAR-20-128 SB1, Clinical Trial Not Allowed

SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance

PAR-20-129 SB1, Clinical Trial Not Allowed

SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development

PAR-20-130 SB1 Clinical Trial Required

SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development

The FOA aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R&D) not typically supported through Phase II or Phase IIB grants or contracts. This may include independent replication of key studies, Investigational New Drug (IND)/Investigational Device Exemption (IDE) enabling studies, clinical studies, manufacturing costs, regulatory assistance, or a combination of services.

Letter of Intent Due Date: 30 days prior to the application due date

PAR-20-211 K18 No Independent Clinical Trials

PAR-20-226 K18 Basic Experimental Studies with Humans Required

Mid-Career Enhancement Awards to Integrate Basic Behavioral, Biomedical, and/or Social Scientific Processes

This Funding Opportunity Announcement (FOA) invites applications from investigators who strive to expand their research trajectories through the acquisition of new knowledge and skills in the areas of basic psychological processes, sociological processes, and/or biomedical pathways—expertise that is beyond and enhances their current areas of expertise. **Application Due Date:** March 17, 2021, March 17, 2022, March 17, 2023

PAR-20-213 T32 Clinical Trial Not Allowed

National Institute of General Medical Sciences Predoctoral Institutional Research Training Grant

NIGMS expects that the proposed research training programs will incorporate didactic, research, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation. **Open Date:** August 25, 2020

PAR-20-221 DP1 Clinical Trial Optional

NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research

The NIDA Avant-Garde award supports innovative basic, clinical and translational research that may lead to improved therapies or preventive interventions for HIV/AIDS for PWUD; creative, new strategies to prevent HIV transmission in high-risk drug using populations; novel approaches to improve HIV and HIV-related comorbid disease outcomes; and creative approaches to eradicating HIV and improving the lives of PWUD living with HIV in general. **Letter of Intent Due Date:** 30 days prior to the application due date **Application Due Date:** August 13, 2020; August 13, 2021; August 15, 2022

PAR-20-224 DP2 Clinical Trial Optional

NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research

The purpose of this program is to support broad spectrum of approaches spanning both basic and clinical research that have the potential to benefit substance using populations with or at risk for HIV/AIDS by reducing HIV incidence, optimizing therapies for HIV and SUD, reducing the impact of comorbid conditions, and ultimately, eradicating HIV. Applications responding to this FOA must clearly describe the intersection of substance use disorders with HIV/AIDS. **Letter of Intent Due Date:** 30 days prior to the application due date **Application Due Date:** August 13, 2020; August 13, 2021; August 15, 2022

PAR-20-225 DP1 Clinical Trial Optional

Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders

The Genetics or Epigenetics of Substance Use Disorders Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction. These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of

addiction. Investigators outside the field of addiction interested in applying their novel approaches to the genetics or epigenetics of addiction are encouraged to apply. **Letter of Intent Due Date:** 30 days prior to the application due date
Application Due Date: October 19, 2020, October 19, 2021, October 19, 2022

[PAR-20-234](#) R01 Clinical Trial Required

NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult Populations

This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site clinical trials (all phases or stages) of interventions focused on specific aging-related issues to reducing transmission, risk, morbidity, mortality, severity, or complications of Coronavirus Disease 2019 (COVID-19). **Application Due Dates:** September 1, 2020; October 1, 2020; November 2, 2020; December 1, 2020; January 4, 2021; and February 1, 2021

[PAR-20-237](#) R01- Clinical Trial Optional

Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations

This Funding Opportunity Announcement (FOA) encourages applications to implement and evaluate community interventions testing 1) the impacts of mitigation strategies to prevent COVID-19 transmission in NIH-designated health disparity populations and other vulnerable groups; and 2) already implemented, new, or adapted interventions to address the adverse psychosocial, behavioral, and socioeconomic consequences of the pandemic on the health of these groups. **Open Date:** July 28, 2020. **Application Due Dates:** August 28, 2020; December 1, 2020

[PAR-20-239](#) R41/R42 Clinical Trial Not Allowed

[PAR-20-244](#) R43/R44 Clinical Trial Not Allowed

Interactive Digital Media STEM Resources for Pre-College and Informal Science Education Audiences

The FOA is to provide opportunities for eligible small business concerns (SBCs) to submit NIH STTR and SBIR grant applications to develop interactive digital media science, technology, engineering and mathematics (STEM) products that address student career choice and health and medicine topics for: (1) pre-kindergarten to grade 12 (P-12) students and pre- and in-service teachers and families or (2) Informal science education (ISE), i.e., outside-the-classroom resources for the general public. **Open Date:** August 04, 2020 **Application Due Date:** September 4, 2020; September 3, 2021; September 2, 2022

[PAR-20-243](#) R01 Clinical Trial Optional

Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19

The purpose of this funding opportunity is to focus on the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), and wearable devices] to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations. **Application Due Date:** August 20, 2020, December 2, 2020, March 2, 2021

[RFA-AG-21-019 \(P30\)](#) clinical trial not allowed

Alzheimers Disease Research Centers (ADRC)

NIA-designated ADRCs serve as major sources of discovery into the nature of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) and into the development of more effective approaches to prevention, diagnosis, care, and therapy. They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators. *Only one application per institution is allowed.* **Application Due Date:** September 15, 2020

[RFA-AG-21-009 \(P30\)](#) clinical trial optional **Artificial Intelligence and Technology Collaboratories for Aging Research**

The AITC program will serve as a national resource to promote the development and implementation of artificial intelligence approaches and technology through demonstration projects to improve care and health outcomes for older Americans, including persons with dementia (PWD) and their caregivers. *Only one application per institution is allowed.* **Application Due Date:** October 1, 2020

[RFA-AG-21-019 \(P30\)](#) clinical trial not allowed

Alzheimers Disease Research Centers (ADRC)

NIA-designated ADRCs serve as major sources of discovery into the nature of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) and into the [development of more effective approaches to prevention, diagnosis, care, and therapy](#). They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators. *Only one application per institution is allowed.* **Application Due Date:** September 15, 2020

[RFA-AG-21-009 \(P30\)](#) clinical trial optional

Artificial Intelligence and Technology Collaboratories for Aging Research

The AITC program will serve as a national resource to promote the development and implementation of artificial intelligence approaches and technology through demonstration projects to improve care and health outcomes for older Americans, including persons with dementia (PWD) and their caregivers. *Only one application per institution is allowed.*

Application Due Date: October 1, 2020

REQUESTS FOR APPLICATIONS (RFA)

[RFA-AI-20-035](#) UM1 Clinical Trial Not Allowed

Martin Delaney Collaboratories for HIV Cure Research

This FOA will support coordinated basic, clinical, and applied research focused on developing strategies to achieve an HIV cure, defined as either sustained viral remission or eradication of HIV infection. While some aspect of clinical research is required, unlike the previous iteration of this RFA, clinical trials will no longer be supported. The application must include at least one private sector entity to facilitate rapid translation of basic discovery research into therapeutic development and testing. LOI is due 30 days prior to the application due date. **Application Receipt Date(s):** Only accepting applications for the AIDS Application Due Date(s) listed.

August Due Dates

[RFA-DA-21-001 \(R34\)](#) Clinical Trial Required **Application Due Date:** August 11, 2020

[RFA-DA-21-002 \(R21\)](#) Clinical Trial Optional **Application Due Date:** August 12, 2020

Reducing Stigma Related to Drug Use in Human Service Settings

One of the most important barriers to the provision and utilization of HIV prevention and care services is stigma, which is defined as an identity marked by disgrace, disapproval or shame, which often leads to discriminatory treatment by others. This RFA will support pilot or feasibility studies of new or adapted interventions to reduce stigma that impedes the provision and utilization of HIV care and prevention services.

September Due Dates

[RFA-CA-20-037](#) U01 Clinical Trial Optional

Tobacco Use and HIV in Low and Middle-Income Countries

The purpose of this Funding Opportunity Announcement (FOA) is to support the development and evaluation of tobacco cessation interventions tailored to HIV-positive populations, including those with comorbidities such as tuberculosis (TB), in low-resource settings in low- and middle-income countries (LMICs).

Letter of Intent Due Date: 30 days prior to the application due date **Application Due Date:** September 24, 2020

[RFA-MH-20-128 \(R01\)](#) clinical trial not allowed

BRAIN Initiative: Standards to Define Experiments Related to the BRAIN Initiative

This FOA solicits applications to develop standards that describe experimental protocols that are being conducted as part of the BRAIN Initiative. It is expected that applications will solicit community input at all stages of the process. It is recommended that the first step of standard development will involve sharing data between different key groups in the experimental community in order to ensure that the developing standard will encompass the data collection efforts of those groups. The developed standard is expected to be broadly disseminated for use and widely available. **Application**

Due Date: September 3, 2020

[RFA-CA-20-019 \(R21\)](#) **Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research**

[RFA-CA-20-020 \(R33\)](#) **Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research**

This FOA solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analyses during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. **Application Due Dates:** September 29, 2020

October Due Dates

[RFA-AG-21-015 \(U19\)](#) clinical trial not allowed

Network for Identification, Evaluation, and Tracking of Older Persons with Superior Cognitive Performance for Their Chronological Age

This FOA invites applications to establish a network to identify, evaluate, track, and conduct research across multiple sites on older adults with superior cognitive performance for their age. The activity would support aggregation of sufficient numbers of these individuals to advance the field's understanding of factors that promote sustained cognitive health and those that are not of primary importance. Uniform identification and uniform data collection will allow the study of the behavioral, neurological, health, genetic, environmental, and lifestyle profiles that lead to sustained cognitive and brain function in advanced age. **Application Due Date:** October 1, 2020

[RFA-AG-21-018 \(R24\)](#) clinical trial not allowed

Artificial Intelligence and Technology Collaboratories for Aging Research Coordinating Center (AITCC)

The AITCC will serve as a hub for the AITC program and will facilitate and coordinate trans-AITC activities. The AITCC will work closely with the NIA Program Officer (e.g., maintain a centralized database to track and synthesize progress and outcomes of each Collaboratory) and, in coordination with all AITC sites, will be responsive to requests generated by key AITC site personnel, NIA, NIH, the scientific community, and the general public. **Application Due Date:** October 1, 2020

[RFA-DA-21-009](#) R01 Clinical Trial Optional

Interventions to Prevent Electronic Nicotine Delivery Systems (ENDS) Use Among Adolescents

The purpose of this funding opportunity announcement is to support (1) research to test the efficacy or effectiveness of interventions to prevent initiation and/or escalation of ENDS (electronic nicotine delivery system) use among adolescents; and (2) research on the impact of tobacco control policies, including ENDS-specific policies, on adolescent ENDS use behavior. For this funding announcement, individuals as young as 12 and as old as 18 encompass the core target age range. **LOI Due Date:** September 19, 2020 **Application Receipt Date:** October 19, 2020

[RFA-AG-21-011 \(R01\)](#) clinical trial optional

Central and Peripheral Control of Balance in Older Adults

This FOA is driven by the need to address a major gap in our understanding of how aging impacts the vestibular system, which, when impaired, contributes to balance problems and an increased risk of falls in older adults. Additionally, given that balance impairment can be attributed to a number of factors (e.g. sensory, motor, cognitive, psychological, and vascular function), understanding the contribution of age-related vestibular loss, and how this interacts with these factors, is critical for informing interventions and treatments for balance problems and falls in older adults. **Application Due Date:** October 2, 2020

[RFA-CA-19-034 \(P20\)](#) clinical trial optional

Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities

The P20 grants will support feasibility and planning activities to build comprehensive cancer health disparities research programs. All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect specific racial/ethnic minority populations. **Application Due Dates:** October 18, 2020

November Due Dates

[RFA-AA-20-009](#) P01 Clinical Trial Optional

Alcohol-HIV/AIDS Program Project Comorbidities, Coinfections, and Complications Research: Intervention and Cross-Cutting Foundational Research

This Funding Opportunity Announcement (FOA) solicits grant applications that propose research that can be translated into interventions in order to reduce infection and transmission of HIV in patients with alcohol use disorders. **Letter of Intent Due Date:** October 17, 2020 **Application Due Date:** November 17, 2020

[RFA-CA-20-004 \(R01\); RFA-CA-20-005 \(R21\)](#) clinical trial optional

Research Answers to NCI's Provocative Questions

These FOAs support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute Provocative Questions Initiative. The current issuance of the PQ Initiative includes an updated set of 9 PQs. Please refer to the funding announcements for the updated list.

Application Due Dates: November 17, 2020

[RFA-CA-20-007 \(R21\)](#) clinical trial optional

Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management

This FOA invites applications for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. **Application Due Dates:** November 18, 2020

[RFA-CA-20-008](#) Early Stage Development (U01)

[RFA-CA-20-009](#) Advanced Development (U24)

[RFA-CA-20-010](#) Sustained Support (U24)

Informatics Technologies for Cancer Research and Management – clinical trial optional

The central mission of these FOAs is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.

Application Due Dates: November 18, 2020

Multiple Due Dates

[RFA-OD-20-008 \(K01\)](#) clinical trial not allowed

[RFA-OD-20-011 \(K01\)](#) clinical trial required

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research

This award provides support and protected time (2-5 years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Candidates for the K01 award must have a research or health-professional doctoral degree.

Application Due Dates: February 8, 2021, October 8, 2021, July 8, 2022

[RFA-OD-20-009 \(K99/R00\)](#) clinical trial not allowed

[RFA-OD-20-010 \(K99/R00\)](#) clinical trial required

Pathway to Independence Award in Tobacco Regulatory Research

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. This program will provide independent research support during this transition in order to help awardees launch competitive, independent research careers.

Application Due Dates: February 8, 2021, October 8, 2021, July 8, 2022

[RFA-OD-19-028 \(R01\)](#) clinical trial optional

Tobacco Regulatory Science

This FOA supports biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP).

Application Due Dates: July 17, 2020, February 13, 2021

[RFA-OD-19-022 \(R21\)](#) clinical trial not allowed

Secondary Analyses of Existing Datasets of Tobacco Use and Health

This FOA supports research proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP).

Application Due Dates: March 8, 2021

[RFA-OD-19-021 \(R21\)](#) clinical trial not allowed

Maximizing the Scientific Value of Existing Biospecimen Collections: Scientific Opportunities for Exploratory Research

This FOA invites applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. **Application Due Dates:** March 8, 2021

[RFA-DA-19-019 \(R43/R44\)](#) clinical trial optional

[RFA-DA-19-020 \(R41/R42\)](#) clinical trial optional

America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis

These FOAs invite applications from US small business concerns to develop technologies to provide science-and research-based solutions to the opioid emergency. **Application Due Dates:** September 8, 2020, April 9, 2021, September 8, 2021

[RFA-NS-20-008 \(R41/R42\); RFA-NS-20-010 \(R43/R44\)](#) clinical trial required

[RFA-NS-20-009 \(R41/R42\); RFA-NS-20-011 \(R43/R44\)](#) clinical trial not allowed

HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management

These FOAs aim to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management. They are focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies. **Application Due Dates:** September 9, 2020, January 6, 2021, April 6, 2021, September 8, 2021, January 6, 2022, April 6, 2022, and September 8, 2022

[RFA-HL-19-024 \(R25\)](#) clinical trial not allowed

Short-Term Research Education Program to Increase Diversity in Health-Related Research

The over-arching goal of this program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce by providing research experiences and related opportunities that enrich the pool of individuals from nationally underrepresented groups who will be available to compete for research opportunities in the mission areas of importance to NHLBI. **Application Due Dates:** September 10, 2020, February 26, 2021

[RFA-NS-19-043 \(K99/R00\)](#) clinical trial not allowed
[RFA-NS-19-044 \(K99/R00\)](#) independent clinical trial required

BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity

This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The BRAIN Initiative is aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a new dynamic picture of the brain that, for the first time, will show how individual cells and complex neural circuits interact in both time and space.

Application Due Dates: October 9, 2020; February 10, 2021; June 9, 2021; October 6, 2021; February 10, 2022; June 8, 2022; October 11, 2022

[RFA-ES-19-011 \(R21\)](#) – clinical trial not allowed

Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences

This FOA supports novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented.

Application Due Dates: Monthly due dates starting November 1, 2019; please refer to the RFA.

Program Announcements Reviewed by an Institute (PAR)

[PAR-20-177](#) **Emergency Awards: Rapid Investigation of SARS-CoV-2, COVID-19 (R21 Clinical Trial Not Allowed)**

[PAR-20-178](#) **Emergency Awards: Rapid Investigation of SARS-CoV-2, COVID-19 (R01 Clinical Trial Not Allowed)**

NIAID is issuing this FOA to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). Applications will be accepted on a rolling basis, beginning on 04/30/2020. PAR-20-177 uses the R21 mechanism, PAR-20-178 uses the R01 grant mechanism.

[PAR-20-179](#) (R01 Clinical Trial Optional)

Advancing Research to Develop Improved Measures and Methods for Understanding Multimorbidity

This FOA invites applications that seek to improve the availability, quality, and utility of data and measures that capture multimorbidity or multiple chronic conditions (MCCs) and the methods for analyzing multimorbidity data. Research supported by this initiative should be designed to discover, develop, and/or evaluate MCC measures/tools that reflect the longitudinally and life course diversity of multimorbidity. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application. Standard dates apply. The first standard due date for this FOA is October 05, 2020.

[PAR-20-180](#) (R01 Clinical Trial Optional)

Identifying Innovative Mechanisms or Interventions that Target Multimorbidity and Its Consequences This FOA invites applications that seek to support the identification of shared mechanisms and development of innovative interventions to address multimorbidity or multiple chronic conditions (MCCs) and its consequences. Of particular interest are interventions that target prevention and treatment of multiple chronic health conditions, including study designs that address therapeutic targets for preventing co-occurring MCCs. The first standard due date for this FOA is October 05, 2020.

[RFA-ES-20-010](#) (R01 Clinical Trial Optional)

U.S. - India Collaborative Environmental Health Research Program (R01 Clinical Trial Optional)

The National Institute of Environmental Health Sciences (NIEHS) and the Indian Council for Medical Research (ICMR) are interested in supporting collaborative research and research training through joint U.S.-India partnerships that address or seek to understand how exposures to toxic environmental insults alter biologic processes and are linked to disease initiation, progression, or morbidity. NIEHS intends to commit \$1,000,000 in FY 2021 to fund 4-5 awards. Application Due Date: October 15, 2020

Program Announcements (PA)

The following opportunities have standard due dates unless noted otherwise:

[PA-20-222](#)

Research Supplements to Promote Diversity in Health-Related Research (Clinical Trial Not Allowed)

Expiration Date: May 08, 2023

Fellowships

PA-20-242

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)

The purpose of NRSA F32 is to support research training of highly promising postdoctoral candidates who have the potential to become productive, independent investigators in scientific health-related research fields relevant to the missions of the participating NIH Institutes and Centers. Applications are expected to incorporate exceptional mentorship. Standard dates apply. **Expiration Date:** May 08, 2023

PA-20-251

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)

The purpose of this NRSA F31 is to Promote Diversity in Health-Related Research award is to enhance the diversity of the health-related research workforce by supporting the research training of predoctoral students from diverse backgrounds including those from groups that are underrepresented in the biomedical, behavioral, or clinical research workforce. Standard dates apply. **Expiration Date:** May 08, 2023

Individual Actions for Sustainability

Use Less Hot Water

